About Modus Outcomes
Modus Outcomes is a company based in Cambridge (United States) founded in 2014 by Stefan Cano was acquired by THREAD in November 2021. Modus Outcomes offers products and services including Patient-Centered Outcome Strategy, Instrument Development, Implementation and Use, and Training. Modus Outcomes operates in a competitive market with competitors including Indegene, IntegriChain, Clinigen, Zuellig Pharma and Fishawack, among others.
- Headquarter Cambridge, United States
- Founders Stefan Cano
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Modus Outcomes
Modus Outcomes offers a comprehensive portfolio of products and services, including Patient-Centered Outcome Strategy, Instrument Development, Implementation and Use, and Training.
Develops strategies for patient outcomes in clinical research.
Creates outcome measures for detecting treatment benefits.
Supports evidence generation for regulatory and market plans.
Offers workshops on patient-centered outcomes and research methods.
Funding Insights of Modus Outcomes
Detailed funding history for Modus Outcomes
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Modus Outcomes
Modus Outcomes has secured backing from 1 investor. Prominent investors backing the company include THREAD.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provider of patient research studies software
|
Locked | Locked | Locked |
Investor details for Modus Outcomes
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Modus Outcomes
Investment portfolio details for Modus Outcomes
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Modus Outcomes
Detailed financials for Modus Outcomes
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Modus Outcomes Comparisons
Peer comparison for Modus Outcomes
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Modus Outcomes
Modus Outcomes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Indegene, IntegriChain, Clinigen, Zuellig Pharma and Fishawack, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Suite solutions are provided for payers and healthcare providers.
|
|
| Locked | Locked | Locked |
Inventory, order and customer relationship management solution for life science suppliers.
|
|
| Locked | Locked | Locked |
Specialty medicines are supplied via clinical trials and access programs.
|
|
| Locked | Locked | Locked |
Healthcare access in Asia is enhanced by Zuellig Pharma.
|
|
| Locked | Locked | Locked |
Fully integrated cross-border services are delivered to global pharmaceutical organizations.
|
|
| Locked | Locked | Locked |
Strategic consulting services are provided to life sciences companies.
|
Detailed competitors of Modus Outcomes
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Modus Outcomes
Complete news archive for Modus Outcomes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Modus Outcomes
Modus Outcomes was founded in 2014.
Modus Outcomes is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Modus Outcomes was founded in 2014 and is based in Cambridge, United States. Operations focus on the biopharma sector, where regulatory support, business consulting, and related services are delivered. Assistance is extended to companies navigating compliance, strategic planning, and operational needs. The firm, co-founded by Stefan Cano, supports clients in achieving regulatory and business objectives within the industry.
Modus Outcomes's top competitors include Indegene, Zuellig Pharma and IntegriChain.
Modus Outcomes offers Patient-Centered Outcome Strategy, Instrument Development, Implementation and Use, and Training.
Modus Outcomes has 1 investor. Key investors include THREAD.